Sponsors › Hangzhou Sciwind Biosciences
Hangzhou Sciwind Biosciences
Every GLP‑1 and incretin trial, approval and scheduled result we hold for Hangzhou Sciwind Biosciences, drawn from ClinicalTrials.gov and Drugs@FDA.
Hangzhou Sciwind Biosciences is a commercial sponsor with 8 trials in the incretin class on file here, across 3 molecules. The programme is split between 1 early-stage trial and 7 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2027-02-27.
- Molecules
- dulaglutide · ecnoglutide · semaglutide
- Trials on file
- 8
- Active trials
- 5
- Results scheduled
- 5
- Approved FDA submissions
- 0
Results due
Trials on file
All 8 incretin trials recorded for this sponsor, active first.